Start date: 
Ecraid Ecraid

PrIMAVeRa

18 Partners

About the Project

‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.

Coordinated by the European Vaccine Inititive (EVI), PrIMAVeRA is a five-year European project funded by the Innovative Medicines Initiative 2 (IMI2) bringing together global leaders in the fields of computational and mathematical modelling, epidemiology, statistics, health economics, microbiology, database management, data science, monoclonal antibody research, and regulatory procedure.

The overarching project goal is to develop an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.

 

Ecraid's Role

Ecraid plays a key role in the consortium by not only providing valuable scientific analysis but, critically, offering direct access to participant-level data essential for refining mathematical models.

The most significant contribution Ecraid brings to the consortium is the wealth of real-world data generated by our Perpetual Observational Studies (POS). These studies are designed to continually enrol patients and collect prospective, standardised data across our pan-European network, ensuring both scale and consistency.

The data provided to PrIMAVeRa will be drawn from our key POS focused on severe infections: complicated urinary tract infections (POS-cUTI) and ventilator-associated pneumonia (POS-VAP). As a testament to the network’s scalability, the two POS have now enrolled over 12,000 patients, providing a robust and detailed dataset.

This extensive data is uniquely positioned to fill critical gaps previously identified by modellers, offering insights into:

  • Infection outcomes, rigorously stratified according to antibiotic susceptibilities.
  • Details on implemented therapies and their duration.
  • Associated hospital resource consumption metrics.

This detailed, participant-level information is vital. It will be used to train and refine the sophisticated mathematical models being developed by the PrIMAVeRa consortium. The objective is to accurately demonstrate the true clinical and economic impact of prophylactic measures, specifically vaccines and mAbs, on curbing AMR development.

Ecraid’s involvement ensures that these crucial models are grounded in the highest quality, most relevant European clinical data available. 

funding